{"favorite_id": 10397, "calc_type": "calculator", "dosing": false, "full_title_en": "Rebound Hyperbilirubinemia Risk Score", "short_title_en": "Rebound Hyperbilirubinemia Risk Score", "medium_description_en": "Estimates risk of rebound hyperbilirubinemia after inpatient phototherapy.", "short_description_en": "Rebound hyperbilirubinemia risk.", "before_use": "", "instructions_en": "<p>Use only in neonates &ge;35 weeks gestational age (GA) treated with first episode inpatient phototherapy.</p>", "slug": "rebound-hyperbilirubinemia-risk-score", "logic_language": "javascript", "md5": "672e45e790d28ef3a1bab9405a74dea3", "cmeVersion": null, "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "publishedAt": "2022-05-03T20:47:37.586Z", "vuid": "865d6b4c-1a24-43e7-a087-dd1096eb48ab", "versionNumber": 1, "isVisibleInListView": true, "disabled": false, "replacement_calc_id": null, "disabled_reason": null, "search_abbreviation_en": ["Rebound Hyperbilirubinemia Risk Score", "rebound hyperbilirubinemia", "hyperbilirubinemia", "hyperbilirubinemia risk score", "infant rebound hyperbilirubinemia", "hyperbilirubinemia risk", "neonatal hyperbilirubinemia"], "seo": {"meta_description_en": "The Rebound Hyperbilirubinemia Risk Score estimates the risk of rebound hyperbilirubinemia after inpatient phototherapy.", "keywords_en": "Rebound Hyperbilirubinemia Risk Score, rebound hyperbilirubinemia, hyperbilirubinemia, hyperbilirubinemia risk score, infant rebound hyperbilirubinemia, hyperbilirubinemia risk, neonatal hyperbilirubinemia"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}, "how_to_use": {"use_case_en": "<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>Use in neonates &ge;35 weeks GA requiring phototherapy to estimate the risk of rebound hyperbilirubinemia prior to discontinuing inpatient phototherapy.</span></p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>Use only in infants with first episode inpatient phototherapy.</span></p>\n</li>\n</ul>", "pearls_pitfalls_en": "<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>Rebound hyperbilirubinemia as defined by the index study is the return of total serum bilirubin (TSB) to or above the American Academy of Pediatrics (AAP) phototherapy threshold (</span><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/15231951\"><span>guidelines</span></a><span>) within 72 hours of phototherapy termination.</span></p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>May be less applicable to older infants (&ge;6 days) and patients with significantly higher relative TSB values at termination of phototherapy.</span></p>\n</li>\n</ul>\n<p></p>", "why_use_en": "<p>Clinicians and parents can make more informed decisions about whether the benefit of earlier phototherapy discontinuation outweighs the risk of rebound hyperbilirubinemia (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28196932\">Chang 2017</a>).</p>"}, "next_steps": {"advice_en": "", "management_en": "<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>The calculator does not recommend a definitive risk level at which to discontinue phototherapy.</span></p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>The decision to continue phototherapy should be made after balancing the risks and costs of prolonging treatment against the benefit of reducing the risk of rebound hyperbilirubinemia.</span></p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>In the derivation study, 34% of infants may have been able to discontinue inpatient phototherapy a day earlier with &lt;4% risk of rebound hyperbilirubinemia.</span></p>\n</li>\n</ul>", "critical_actions_en": "<p>Ease of follow up TSB testing and hardship of readmission should be considered in the decision to stop or continue phototherapy in infants regardless of risk score.</p>"}, "about": {"formula_en": "<p dir=\"ltr\"><span>The Rebound Hyperbilirubinemia Risk Score is calculated based on the following inputs:</span></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>Gestational age (GA) &lt;38 weeks (yes or no).</span></p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\"><span>Age at phototherapy initiation, hours.</span></li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\"><span>Total serum bilirubin (TSB) at phototherapy termination.</span></p>\n</li>\n</ul>\n<p dir=\"ltr\"><span>American Academy of Pediatrics (AAP) phototherapy threshold is determined as follows:</span><b></b></p>\n<div dir=\"ltr\" align=\"left\">\n<table style=\"width: 79.69283276450513%;\"><colgroup><col style=\"width: 41.19047619047619%;\"><col style=\"width: 58.57142857142858%;\"></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Age, hours</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>AAP Threshold, mg/dL</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>25-48</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>15 mg/dL</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>49-72</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>18 mg/dL</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>&gt;72</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>20 mg/dL</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Note: formula assumes TSB and AAP threshold units in mg/dL.</p>\n</div>\n<p dir=\"ltr\"><span>Rebound Hyperbilirubinemia Risk Score = 15*(GA &lt;38 weeks) - 7*(age at phototherapy initiation, days) - 4*(AAP threshold - TSB) + 50</span></p>\n<p></p>", "more_info_en": "<div dir=\"ltr\" align=\"left\">\n<table style=\"width: 74.8268%;\"><colgroup><col width=\"146\" style=\"width: 41.1535%;\"><col width=\"302\" style=\"width: 58.8465%;\"></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>RH Risk Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk of Rebound Hyperbilirubinemia</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>&le;9</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>0.3%</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10-19</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>1.8%</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20-29</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>6.1%</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>30-39</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>17.4%</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>40-49</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>25.8%</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>&ge;50</span></p>\n</td>\n<td>\n<p dir=\"ltr\"><span>40.5%</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>", "evidence_based_medicine_en": "<p dir=\"ltr\"><span>The prediction rule was derived from a retrospective cohort study of 7,048 infants treated with first episode inpatient phototherapy before age 14 days in a single integrated health system between 2012-2014 (</span><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28196932\"><span>Chang 2017</span></a><span>). The study excluded infants who had &ge;2 TSB measurements and infants with conjugated bilirubin level &ge;2 mg/dl before or during their first phototherapy admission. Mean age at initiation of phototherapy in the derivation study was 2.3 days; mean age at termination of phototherapy was 3.6 days and mean estimated TSB at termination of phototherapy was 9.8 mg/dL.</span></p>\n<p dir=\"ltr\"><span>Significant predictors of rebound hyperbilirubinemia identified in the study were: gestational age &lt;38 weeks, younger age at phototherapy initiation, and TSB relative to the treatment threshold at phototherapy termination. The rule was internally validated using a split sample validation method. The area under the ROC curve was 0.89 in the derivation data set and 0.88 in the validation data set.</span></p>", "references_list": {"Validation": [{"text": "Chou JH. Predictive models for neonatal follow-up serum bilirubin: model development and validation. JMIR Med Inform. 2020;8(10):e21222.", "href": "https://pubmed.ncbi.nlm.nih.gov/33118947/"}], "Outcomes": [], "Validations": [], "Original/Primary Reference": [{"text": "Chang PW, Kuzniewicz MW, McCulloch CE, Newman TB. A clinical prediction rule for rebound hyperbilirubinemia following inpatient phototherapy. Pediatrics. 2017;139(3):e20162896.", "href": "https://pubmed.ncbi.nlm.nih.gov/28196932/"}], "Other References": [{"text": "Porter ML, Dennis MBL. Hyperbilirubinemia in the term newborn. AFP. 2002;65(4):599.", "href": "https://www.aafp.org/afp/2002/0215/p599.html"}, {"text": "Chang PW, Newman TB. A simpler prediction rule for rebound hyperbilirubinemia. Pediatrics. 2019;144(1):e20183712.", "href": "https://pubmed.ncbi.nlm.nih.gov/31196939/"}], "Clinical Practice Guidelines": [{"text": "Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859.", "href": "https://pubmed.ncbi.nlm.nih.gov/35927462/"}], "Manufacturer Website": []}}, "creator": [{"qa_en": null, "approved": null, "name": "Dr. Pearl W. Chang", "creator_info": {"deceased": null, "about_en": "<p><span>Pearl W. Chang, MD, is a pediatrics specialist, currently practicing at Seattle Children&rsquo;s Hospital in Washington. She graduated with honors from Stanford University School of Medicine in 2011. Dr. Chang&rsquo;s primary research is focused on urinary tract infections and neonatal jaundice.</span></p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-pearl-w-chang.jpg"}}], "contributor": {"expert_name": [{"description": "", "firstName": "Chionye", "img": "", "lastName": "Ossai", "name": "Chionye Ossai, MD", "target": "", "signedCOI": false, "hasDisclosure": []}]}}, "input_schema": [{"type": "radio", "name": "gest", "default": null, "show_points": false, "optional": false, "conditionality": null, "tips_en": "", "label_en": "<p>Gestational age (GA)</p>", "option_fhir_rules": null, "options": [{"label": "<38 weeks", "value": 1}, {"label": "\u226538 weeks", "value": 0}], "mdcalc_info_concept": null}, {"conditionality": null, "tips_en": "", "optional": false, "name": "age", "type": "textbox", "label_en": "<p>Age at phototherapy initiation, hours</p>", "default": null, "inct": null, "unit": "age_hours", "fhir_rules": null, "unit_info": {"name": "RH Age", "conversion": 1, "error_min": 25, "error_max": 336, "warn_min": 25, "warn_max": 336, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "hours", "units_us": "hours"}}, {"conditionality": null, "tips_en": "", "optional": false, "name": "tsb", "type": "textbox", "label_en": "<p>Total serum bilirubin (TSB)</p>", "default": null, "inct": null, "unit": "bili", "fhir_rules": null, "unit_info": {"name": "Bilirubin", "conversion": 17.104, "error_min": 1e-08, "error_max": 50, "warn_min": 0, "warn_max": 20, "normal_max_si": 32.49, "normal_min_si": 5.13, "normal_min_us": 0.3, "units_si": "\u00b5mol/L", "units_us": "mg/dL", "normal_max_us": 1.9}}], "chief_complaint_en": ["Abdominal Pain", "Chest Pain", "Fatigue", "Fever", "Jaundice", "Nausea", "Weakness"], "specialty_en": ["Critical Care (Neonatal)", "Critical Care (Pediatric)", "Hematology and Oncology", "Hepatology", "Hospitalist Medicine", "Internal Medicine", "Pediatric Subspecialty", "Pediatrics"], "purpose_en": ["Prognosis"], "system_en": ["Endocrine and Metabolic"], "disease_en": ["Neonatal Hyperbilirubinemia"], "tags": [], "versions": [], "related_calcs": [{"calcId": 10167, "short_title_en": "Neonatal Hyperbilirubinemia Risk", "slug": "hour-specific-risk-neonatal-hyperbilirubinemia"}, {"calcId": 10471, "short_title_en": "Thakar Score", "slug": "acute-renal-failure-cardiac-surgery-thakar-score"}, {"calcId": 10470, "short_title_en": "VIRSTA Score", "slug": "virsta-score"}]}